Theriva Biologics Inc (TOVX) Stock Price, Quote & News

Company Profile

Theriva Biologics, Inc., a clinical-stage company, develops therapeutics to treat cancer and related diseases in areas of high unmet need in the United States. The company's lead product candidate is VCN-01, a clinical stage oncolytic human adenovirus that is in a Phase 2 clinical study for the treatment of pancreatic cancer; a Phase 1 clinical study for the treatment of retinalblastoma; a Phase 1 clinical study for the treatment of head and neck squamous cell carcinoma, ovarian cancer, colorect...

Industry: Biotechnology

Sector: Healthcare

Phone: 301 417 4364

Website: therivabio.com

Address:

9605 Medical Center Drive, Suite 270, Rockville, United States

andytran1976 Mar. 15 at 7:10 PM

$TOVX @StockBoySam No, when the company sell the warrant at 0.54 a share, it will get nearly $9M fresh money. so, you add 9m with 15m cash on hand and divide by the share outstanding. so, $24M divide by 61m share will give you $0.40 in cash per share. Factor that in with the pipeline will give over $2 a share in fair value. And if it gets a partner, it will reach the $7 target value.

1 · Reply

StockBoySam Mar. 15 at 5:24 PM

$TOVX @andytran1976 I have enough shares to vote. The stock price currently is .18, and that is the current market value. The company wants to increase the number of the shares by giving away 16,000,000 warrants. It will devalue the stock price substantially. I am not sure where you went to school, but diluting a company giving away warrants will further dilute the value of the stock to around .11 per share; and the whole story behind the 16,000,000 warrants is the company "Gifted" these warrants during the last "pump and dump" in October. The warant holders profited .35 a share and drove the price down. You sound like you are "pumping" for the company!

1 · Reply

StockBoySam Mar. 15 at 4:44 PM

$TOVX I am voting absolute NO on the next vote. Who knew about the upcoming vote a day or two before it was announced here and is promoting a yes vote? It looks as if we have a shill here! I wonder who it could be? Obviously...A shill is a person who pretends to be an impartial customer or enthusiastic bystander to promote a product, service, or agenda, often for hidden personal gain. Their purpose is to manipulate others into participating in scams, purchases, or supporting a cause by creating false social proof. Why vote vote diluting the stock that has been diluted time and time again?

1 · Reply

StockBoySam Mar. 15 at 4:31 PM

$TOVX StockBoySam Lawrence @StockBoySam I like this video. If what he's saying is true, TOVX seems like the board members are only concerned with their pockets, not the shareholders, or having their priority set on curing cancer. I hope I’m wrong. When can the board members be replaced? This guy in the video looks like he will fight for us, knows so much about the board members history, and appears genuine to search and be involved somehow in finding the cure. Put him on the board!

0 · Reply

StockBoySam Mar. 15 at 4:28 PM

$TOVX $TOVX @neily51 I am not sure if my last message posted, but the gentleman in the video you posted appears to have done extensive research on TOVX, the board members, their past dealings, and is if anyone could be a new board member to keep the company's integrity in check, I would vote for him.

0 · Reply

ChartChartist Mar. 15 at 4:09 PM

$TOVX lets see .165 bounce off low again then another run $HPK perfect channel $EZRA i like it here $CLIK hot float size. Some volumes finally $AEHL horney for gains and they have been dropping this too far on low volumes; so a flip is coming. Great entry spots.

0 · Reply

Blu66 Mar. 14 at 6:00 PM

$TOVX Institutional and Speculative Investors Institutional Investors: Despite low capitalization, institutions such as Geode Capital Management and Anson Funds Management have maintained or opened positions in the stock. "High-Risk/High-Reward" speculators: With a reduced market capitalization (about $6.5 million) and cash reserves covering operations through the first quarter of 2027, the stock is monitored for possible clinical "catalysts" or acquisitions. Sector Analysts: Some analysts maintain positive ratings with target prices significantly higher than current quotes (up to $7), betting on the success of Phase 3.

2 · Reply

Blu66 Mar. 14 at 5:51 PM

$TOVX buy… Monday up

0 · Reply

Blu66 Mar. 14 at 5:50 PM

$TOVX Financial and Market Data (as of March 14, 2026) Listing: Listed on the NYSE American with the TOVX symbol. Recent Trend: The stock showed high volatility, with a price around $0.17 - $0.19. 2025 Results: The company recently reported financial results for the entire year ended December 31, 2025. Analyst Target: Despite the current low price, some analysts maintain a "Buy" rating with significantly higher long-term price targets, based on the pipeline's clinical potential. http://Investing.com - Quotes, Stock Exchange, Economics and Finance

0 · Reply

andytran1976 Mar. 13 at 6:08 PM

$TOVX Just added more, second time today!

1 · Reply

Theriva™ Biologics Announces Positive Scientific Advice from the European Medicines Agency (EMA) on the Design of a Phase 3 Trial of VCN-01 in Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Oct 24, 2025, 2:31 PM EDT - 5 months ago

Theriva Biologics Provides Response to Unusual Market Action

Oct 16, 2025, 8:11 AM EDT - 5 months ago

Theriva™ Biologics Announces a Warrant Inducement Transaction for $4.0 Million in Gross Proceeds

Oct 6, 2025, 8:00 AM EDT - 5 months ago

Theriva™ Biologics Announces Presentation Describing Next Generation Oncolytic Adenovirus VCN-12 at the 32nd Annual Congress of the European Society of Gene & Cell Therapy (ESGCT)

Aug 11, 2025, 8:00 AM EDT - 7 months ago

Theriva™ Biologics Reports Second Quarter 2025 Operational Highlights and Financial Results

May 14, 2025, 8:40 AM EDT - 10 months ago

Theriva™ Biologics Reports First Quarter 2025 Operational Highlights and Financial Results

May 8, 2025, 4:30 PM EDT - 11 months ago

Theriva Biologics Announces Closing of $7.5 Million Public Offering

May 7, 2025, 9:17 AM EDT - 11 months ago

Theriva Biologics Announces Pricing of $7.5 Million Public Offering

Apr 10, 2025, 8:00 AM EDT - 1 year ago

Theriva Biologics Announces Presentation of Data from the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

Mar 19, 2025, 8:10 AM EDT - 1 year ago

Theriva™ Biologics to Present at the 2025 NeauxCancer Conference

Mar 6, 2025, 4:10 PM EST - 1 year ago

Theriva™ Biologics Reports Full-Year 2024 Operational Highlights and Financial Results

Mar 5, 2025, 4:05 PM EST - 1 year ago

Theriva™ Biologics to Participate in the Q1 Investor Summit Virtual

Dec 5, 2024, 8:00 AM EST - 1 year ago

Theriva™ Biologics Announces U.S. FDA Guidance on Design of Phase 3 Study of VCN-01 for the Treatment of Metastatic Pancreatic Cancer

Oct 16, 2024, 8:00 AM EDT - 1 year ago

Theriva Biologics Announces Orphan Medicinal Product Designation Granted by the European Commission to VCN-01 for the Treatment of Retinoblastoma

Sep 26, 2024, 9:06 PM EDT - 1 year ago

Theriva Biologics Announces Pricing of $2.5 Million Public Offering

Sep 23, 2024, 8:00 AM EDT - 1 year ago

Theriva™ Biologics Achieves Target Patient Enrollment in the VIRAGE Phase 2b Trial of VCN-01 with Gemcitabine/nab-Paclitaxel for the Treatment of Metastatic Pancreatic Cancer

Sep 16, 2024, 8:00 AM EDT - 1 year ago

Theriva™ Biologics Awarded Manufacturing Funding from the Spanish Government's National Knowledge Transfer Program

Aug 16, 2024, 4:05 PM EDT - 1 year ago

Theriva Biologics Announces Reverse Stock Split

Jul 31, 2024, 8:15 AM EDT - 1 year ago

Theriva™ Biologics Receives Rare Pediatric Drug Designation by the U.S. FDA for VCN-01 for the Treatment of Retinoblastoma

May 23, 2024, 8:15 AM EDT - 1 year ago

Theriva™ Biologics Announces Fast Track Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Metastatic Pancreatic Cancer

May 14, 2024, 8:00 AM EDT - 1 year ago

Theriva™ Biologics to Participate in the A.G.P. Virtual Healthcare Conference

May 7, 2024, 7:00 AM EDT - 2 years ago

Theriva™ Biologics Reports First Quarter 2024 Operational Highlights and Financial Results

Apr 25, 2024, 8:15 AM EDT - 2 years ago

Theriva™ Biologics to Discuss the Trial Design for VIRAGE - a Phase 2b Clinical Study of Systemically Administered VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma - at the 2024 American Society of Clinical Oncology (ASCO) Annua

$Theriva™ Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma$

Apr 23, 2024, 7:00 AM EDT - 2 years ago

Theriva™ Biologics Announces Positive Topline Data from Investigator Sponsored Phase 1 Trial of Intravitreal VCN-01 in Pediatric Patients with Refractory Retinoblastoma

Apr 22, 2024, 4:35 PM EDT - 2 years ago

Theriva™ Biologics to Present Preclinical Data Supporting the Potential Synergy of VCN-01 and First-Line Pancreatic Cancer Chemotherapy Regimens at the American Society for Cell and Gene Therapy 27th Annual Meeting

Apr 8, 2024, 8:00 AM EDT - 2 years ago

Theriva™ Biologics Announces Presentation at the American Society for Cell and Gene Therapy 27th Annual Meeting

Mar 25, 2024, 12:01 PM EDT - 2 years ago

Theriva Biologics, Inc. (TOVX) Q4 2023 Earnings Call Transcript

Mar 25, 2024, 7:30 AM EDT - 2 years ago

Theriva™ Biologics Reports Full-Year 2023 Operational Highlights and Financial Results

Mar 19, 2024, 8:00 AM EDT - 2 years ago

Theriva™ Biologics to Host Conference Call and Webcast to Discuss Full Year 2023 Operational Highlights and Financial Results

Mar 11, 2024, 8:00 AM EDT - 2 years ago

Theriva™ Biologics to Participate in the BIO-Europe Spring Conference

Feb 7, 2024, 8:00 AM EST - 2 years ago

Theriva Biologics Announces Positive Recommendation from the Independent Data Monitoring Committee of VIRAGE, the Phase 2b Clinical Trial of VCN-01 in Combination with Chemotherapy for Metastatic Pancreatic Ductal Adenocarcinoma

Jan 16, 2024, 8:00 AM EST - 2 years ago

Theriva Biologics to Participate in the B. Riley Securities Annual Oncology Conference

Nov 17, 2023, 12:51 PM EST - 2 years ago

Theriva Biologics, Inc. (TOVX) Q3 2023 Earnings Call Transcript

Nov 13, 2023, 8:00 AM EST - 2 years ago

Theriva™ Biologics Reports Third Quarter 2023 Operational Highlights and Financial Results

Nov 6, 2023, 4:05 PM EST - 2 years ago

Theriva Biologics to Host Conference Call and Webcast to Discuss Third Quarter 2023 Operational Highlights and Financial Results

Nov 2, 2023, 4:15 PM EDT - 2 years ago

Theriva™ Biologics to Participate in the BIO-Europe Conference

Nov 2, 2023, 8:00 AM EDT - 2 years ago

Theriva™ Biologics and Sant Joan de Déu-Barcelona Children's Hospital Advance Strategic Collaboration to Explore the Combination of VCN-01 with Topoisomerase Inhibitors to Treat Cancer

Oct 23, 2023, 7:00 AM EDT - 2 years ago

Theriva™ Biologics Presents Survival Outcomes Data from Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck at ESMO Congress 2023

Oct 16, 2023, 8:00 AM EDT - 2 years ago

Theriva™ Biologics Announces Presentation at ESMO Congress 2023 Featuring Survival Outcomes in Phase 1 Study Evaluating VCN-01 in Combination with Durvalumab in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Sep 28, 2023, 8:00 AM EDT - 2 years ago

Theriva Biologics to Participate in the Emerging Growth Conference

Aug 12, 2023, 1:52 PM EDT - 2 years ago

Theriva Biologics, Inc. (TOVX) Q2 2023 Earnings Call Transcript

Aug 8, 2023, 8:00 AM EDT - 2 years ago

Theriva™ Biologics Reports Second Quarter 2023 Operational Highlights and Financial Results

Aug 2, 2023, 7:00 AM EDT - 2 years ago

Theriva™ Biologics Announces Key Progress in VIRAGE, an Ongoing, Multinational Phase 2b Trial of VCN-01 in Combination with Chemotherapy in Pancreatic Ductal Adenocarcinoma

Aug 1, 2023, 4:05 PM EDT - 2 years ago

Theriva Biologics to Host Conference Call and Webcast to Discuss Second Quarter 2023 Operational Highlights and Financial Results

Jun 27, 2023, 4:10 PM EDT - 2 years ago

Theriva Biologics Announces Orphan Drug Designation Granted by the U.S. FDA for VCN-01 for the Treatment of Pancreatic Cancer

May 23, 2023, 8:00 AM EDT - 3 years ago

Theriva Biologics Announces Appointment of Ramon Alemany, Ph.D., to Senior Vice President of Discovery

May 11, 2023, 8:00 AM EDT - 3 years ago

Theriva Biologics Reports First Quarter 2023 Operational Highlights and Financial Results

May 4, 2023, 8:00 AM EDT - 3 years ago

Theriva Biologics to Host Conference Call and Webcast to Discuss First Quarter 2023 Operational Highlights and Financial Results

Apr 13, 2023, 8:00 AM EDT - 3 years ago

Theriva Biologics Announces Presentation of Data from Cohort 1 of the Phase 1b/2a Clinical Trial of SYN-004 (ribaxamase) in Allogeneic Hematopoietic Cell Transplant Recipients

Mar 30, 2023, 8:00 AM EDT - 3 years ago

Theriva Biologics Reports Fourth Quarter and Full-Year 2022 Operational Highlights and Financial Results

andytran1976 Mar. 15 at 7:10 PM

1 · Reply

StockBoySam Mar. 15 at 5:24 PM

1 · Reply

StockBoySam Mar. 15 at 4:44 PM

1 · Reply

StockBoySam Mar. 15 at 4:31 PM

0 · Reply

StockBoySam Mar. 15 at 4:28 PM

0 · Reply

ChartChartist Mar. 15 at 4:09 PM

0 · Reply

Blu66 Mar. 14 at 6:00 PM

2 · Reply

Blu66 Mar. 14 at 5:51 PM

$TOVX buy… Monday up

0 · Reply

Blu66 Mar. 14 at 5:50 PM

0 · Reply

andytran1976 Mar. 13 at 6:08 PM

$TOVX Just added more, second time today!

1 · Reply

Blu66 Mar. 13 at 5:45 PM

$TOVX buy buy

0 · Reply

Blu66 Mar. 13 at 5:45 PM

$TOVX Upcoming Events: Further analysis of the Phase 2b study (VIRAGE) will be presented to the American Association of Cancer Research (AACR) in San Diego, from April 17 to 22, 2026. http://Therivabio.com http://Therivabio.com

0 · Reply

Blu66 Mar. 13 at 5:44 PM

$TOVX Financial updates (as of March 12, 2026) Liquidity: As of December 31, 2025, the company had $13.1 million. As of February 26, 2026, liquidity rose to about 15.2 million dollars, guaranteeing operations until the first quarter of 2027. Net Results: For the year 2025, Theriva reported a net loss of $25.25 million ($2.08 per share), an improvement over the loss of $19.03 per share in the previous year. Expenses: General and administrative expenses increased to 15.45 million dollars (compared to 7.40 million in 2024), while research and development expenses fell to 8.60 million dollars.

0 · Reply

Blu66 Mar. 13 at 5:42 PM

$TOVX Operational & Financials: As of February 26, 2026, cash and cash equivalents were approximately $15.2 million, providing a cash runway into the first quarter of 2027. Upcoming Milestones: 1H 2026: An End-of-Phase 2 meeting with the FDA is planned to finalize the Phase 3 study design for VCN-01 in PDAC. April 2026: Data from the VIRAGE Phase 2b study of VCN-01 will be presented at the AACR meeting.

0 · Reply

Blu66 Mar. 13 at 5:41 PM

$TOVX Theriva™ Biologics (TOVX) is focusing on its oncology pipeline, specifically advancing VCN-01 for pancreatic cancer (PDAC) following positive EMA feedback. Key developments include licensing SYN-020 to Rasayana Therapeutics in February 2026, conducting Phase 1 trials for retinoblastoma, and preparing for a Phase 3 trial for VCN-01, with a cash runway projected into 1Q27. CNBC CNBC +4 Key 2025–2026 News & Updates VCN-01 (Oncolytic Virus): The European Medicines Agency (EMA) provided positive scientific advice on the Phase 3 trial design for VCN-01 in combination with chemotherapy for metastatic pancreatic ductal adenocarcinoma (PDAC), agreeing on key endpoints and trial design. Pipeline Focus: The company is focusing on its oncolytic virus platform (VCN-01) and has licensed out its GI-focused assets, specifically SYN-020, to Rasayana Therapeutics for up to $38M in milestones, plus royalties.

0 · Reply

Blu66 Mar. 13 at 5:39 PM

$TOVX They should answer x phase 3 ... trust me.. they are accumulating to make it fly

0 · Reply

Blu66 Mar. 13 at 5:31 PM

$TOVX Big volumes will arrive....prepare them for a portentously rise

1 · Reply

Blu66 Mar. 13 at 5:29 PM

$TOVX road to 1$

3 · Reply

Blu66 Mar. 13 at 5:28 PM

$TOVX Great news coming next week!!!!

0 · Reply

Blu66 Mar. 13 at 5:27 PM

$TOVX Don't talk nonsense

1 · Reply

neily51 Mar. 13 at 5:09 PM

$TOVX 10c incoming. Followed by delisting or OTC .running out of time .

0 · Reply

Blu66 Mar. 13 at 3:25 PM

$TOVX buy another 50000 share to 0.177

0 · Reply

Market Cap	5.91M
Revenue (ttm)	0.00
Net Income (ttm)	-25.65M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.24

Volume	1,928,000
Avg Vol	8,555,540
Day's Range	N/A - N/A
Shares Out	33.74M
Stochastic %K	18%
Beta	0.54
Analysts	Hold
Price Target	$4.00